Treatment of Multiorgan Sarcoidosis With Tofacitinib
Objective Sarcoidosis is an idiopathic inflammatory disorder that is difficult to treat. There is accumulating evidence that constitutive activation of Janus kinase–signal transducer and activator of transcription (JAK‐STAT) signaling occurs in sarcoidosis and represents a target for treatment. Here...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-02-01
|
| Series: | ACR Open Rheumatology |
| Online Access: | https://doi.org/10.1002/acr2.11112 |
| _version_ | 1818329020396208128 |
|---|---|
| author | William Damsky Bryan D. Young Brett Sloan Edward J. Miller J. Antonio Obando Brett King |
| author_facet | William Damsky Bryan D. Young Brett Sloan Edward J. Miller J. Antonio Obando Brett King |
| author_sort | William Damsky |
| collection | DOAJ |
| description | Objective Sarcoidosis is an idiopathic inflammatory disorder that is difficult to treat. There is accumulating evidence that constitutive activation of Janus kinase–signal transducer and activator of transcription (JAK‐STAT) signaling occurs in sarcoidosis and represents a target for treatment. Here we report the efficacy of tofacitinib, a Janus kinase (JAK) inhibitor, in a single patient with multiorgan sarcoidosis. Methods A patient with long‐standing multiorgan sarcoidosis who was unresponsive to other commonly used therapies, including methotrexate, prednisone, and tumor necrosis factor α blockade, was treated with tofacitinib. Results Tofacitinib treatment resulted in clinical remission of cutaneous sarcoidosis lesions and resolution of positron emission tomography avid lesions in internal organs after 6 months. An evaluation of lesional tissue and blood before and during treatment showed resolution of granulomatous inflammation and normalization of disease biomarkers. Conclusion This case illustrates the promise of JAK inhibition as a strategy to treat recalcitrant sarcoidosis and suggests that further study of JAK inhibitors in sarcoidosis is needed. |
| first_indexed | 2024-12-13T12:41:25Z |
| format | Article |
| id | doaj.art-6757ea154fef423bb9f32c8812dda97d |
| institution | Directory Open Access Journal |
| issn | 2578-5745 |
| language | English |
| last_indexed | 2024-12-13T12:41:25Z |
| publishDate | 2020-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | ACR Open Rheumatology |
| spelling | doaj.art-6757ea154fef423bb9f32c8812dda97d2022-12-21T23:45:38ZengWileyACR Open Rheumatology2578-57452020-02-012210610910.1002/acr2.11112Treatment of Multiorgan Sarcoidosis With TofacitinibWilliam Damsky0Bryan D. Young1Brett Sloan2Edward J. Miller3J. Antonio Obando4Brett King5Department of Dermatology Yale School of Medicine New Haven Connecticut USADepartment of Internal Medicine Section of Cardiovascular Medicine, Yale School of Medicine New Haven Connecticut USADepartment of Dermatology University of Connecticut School of Medicine Farmington Connecticut USADepartment of Internal Medicine Section of Cardiovascular Medicine, Yale School of Medicine New Haven Connecticut USAVeterans Administration Veterans Hospital West Haven Connecticut USADepartment of Dermatology Yale School of Medicine New Haven Connecticut USAObjective Sarcoidosis is an idiopathic inflammatory disorder that is difficult to treat. There is accumulating evidence that constitutive activation of Janus kinase–signal transducer and activator of transcription (JAK‐STAT) signaling occurs in sarcoidosis and represents a target for treatment. Here we report the efficacy of tofacitinib, a Janus kinase (JAK) inhibitor, in a single patient with multiorgan sarcoidosis. Methods A patient with long‐standing multiorgan sarcoidosis who was unresponsive to other commonly used therapies, including methotrexate, prednisone, and tumor necrosis factor α blockade, was treated with tofacitinib. Results Tofacitinib treatment resulted in clinical remission of cutaneous sarcoidosis lesions and resolution of positron emission tomography avid lesions in internal organs after 6 months. An evaluation of lesional tissue and blood before and during treatment showed resolution of granulomatous inflammation and normalization of disease biomarkers. Conclusion This case illustrates the promise of JAK inhibition as a strategy to treat recalcitrant sarcoidosis and suggests that further study of JAK inhibitors in sarcoidosis is needed.https://doi.org/10.1002/acr2.11112 |
| spellingShingle | William Damsky Bryan D. Young Brett Sloan Edward J. Miller J. Antonio Obando Brett King Treatment of Multiorgan Sarcoidosis With Tofacitinib ACR Open Rheumatology |
| title | Treatment of Multiorgan Sarcoidosis With Tofacitinib |
| title_full | Treatment of Multiorgan Sarcoidosis With Tofacitinib |
| title_fullStr | Treatment of Multiorgan Sarcoidosis With Tofacitinib |
| title_full_unstemmed | Treatment of Multiorgan Sarcoidosis With Tofacitinib |
| title_short | Treatment of Multiorgan Sarcoidosis With Tofacitinib |
| title_sort | treatment of multiorgan sarcoidosis with tofacitinib |
| url | https://doi.org/10.1002/acr2.11112 |
| work_keys_str_mv | AT williamdamsky treatmentofmultiorgansarcoidosiswithtofacitinib AT bryandyoung treatmentofmultiorgansarcoidosiswithtofacitinib AT brettsloan treatmentofmultiorgansarcoidosiswithtofacitinib AT edwardjmiller treatmentofmultiorgansarcoidosiswithtofacitinib AT jantonioobando treatmentofmultiorgansarcoidosiswithtofacitinib AT brettking treatmentofmultiorgansarcoidosiswithtofacitinib |